Fateme Sefid

Dr. Fateme Sefid

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2021 in International Journal of Peptide Research and Therapeutics
Verified
Journal Article
Closed access
PDF file
MTMaryam Touhidinia
Maryam Touhidinia
FSFateme Sefid
Fateme Sefid
MBMozhgan Bidakhavidi
Mozhgan Bidakhavidi

15 February 2021 in In Silico Pharmacology
Verified
Journal Article
Closed access
FSFateme Sefid
Fateme Sefid
ZPZahra Payandeh
Zahra Payandeh
GAGhasem Azamirad
Ghasem Azamirad
Behzad BaradaranBehzad Baradaran
Behzad Baradaran
MNMohsen Nabi-Afjadi
Mohsen Nabi-Afjadi
MAMahnam Alaei Ardakani
Mahnam Alaei Ardakani


17 November 2018 in International Journal of Peptide Research and Therapeutics
Verified
Journal Article
Closed access
PDF file
SEShirin Eyvazi
Shirin Eyvazi
ZPZahra Payandeh
Zahra Payandeh
SKSaeed Khalili
Saeed Khalili
FSFateme Sefid
Fateme Sefid
EOElaheh Ouladsahebmadarek
Elaheh Ouladsahebmadarek

16 October 2024 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
NINastaran Injinari
Nastaran Injinari
SASamira Asadollahi
Samira Asadollahi
FSFateme Sefid
Fateme Sefid
MAMaedeh Arshadi
Maedeh Arshadi
SHSaeedeh Sadat Hosseini
Saeedeh Sadat Hosseini
FAFatemeh Aghaeimeybodi
Fatemeh Aghaeimeybodi
Although several genetic biomarkers have been reported in the tocilizumab (TCZ) response in rheumatoid arthritis, no studies have addressed the pharmacogenomics effect of TCZ in COVID-19. In this prospective longitudinal study, 95 individuals with severe COVID-19 were selected between 2020–2022. The recovery process was measured at 24 h, 48 h, and 10 days before and after taking TCZ. All participants were genotyped using RFLP-PCR. Different genotypes of FCGR2A rs1801274 and IL-6R rs2228145 were compared in terms of the recovery process. 43.2% of patients were male and 56.8% were female with an average age of 58.20(± 16.214) years. The GA genotype for FCGR2A rs1801274 increased the risk of death (OR = 2.83, P = 0.038) and ventilation (OR = 2.71, P = 0.047) in TCZ-treated individuals. However, there was no risk of death and ventilation with IL-6R rs2228145 (P > 0.05). Additionally, docking analysis showed that not only IL6R but also FCGR2A can be a ligand for TCZ. This study provides valuable insights into the impact of genetic variations on the response rate of TCZ in COVID-19 patients. The GA genotype for FCGR2A rs1801274 was associated with poor treatment outcomes.

1 January 2025 in Journal of Diabetes Research
Verified
Journal Article
Open access
FSFateme Sefid
Fateme Sefid
MTMasoud Dehghan Tezerjani
Masoud Dehghan Tezerjani
SASamira Asadollahi
Samira Asadollahi
SMSeyed Ali Madani
Seyed Ali Madani
TPTayebeh Pardal
Tayebeh Pardal
MMMohammad Yahya Vahidi Mehrjardi
Mohammad Yahya Vahidi Mehrjardi
Background: Maturity‐onset diabetes of the young (MODY), a common type of monogenic diabetes caused by a pathogenic variant in a single gene, is characterized by starting at an early age, autosomal dominant inheritance, and decreased secretion of insulin. Despite its clinical importance, its accurate diagnosis is challenging, and it is often misdiagnosed as other types of diabetes. Therefore, understanding the genetic basis of MODY can improve diagnostic accuracy. Methods: We initially performed genetic counseling for 2964 probands who visited the Yazd Diabetes Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran, between 2018 and 2022. Clinical assessments and pedigree analyses were conducted for the accurate clinical diagnosis and management of diabetes. Among these, 11 probands with unknown types of diabetes who met specific criteria, including an inheritance pattern across at least three generations, at least seven affected individuals, and probands being under age 55, were selected for whole‐exome sequencing (WES). Finally, variants were verified by Sanger sequencing, pedigree analysis, and segregation analysis. Results: WES analysis detected pathogenic variants in two families, which confirmed MODY. Family 202 had a novel missense variant (GCK: c.484G > C; p.Gly162Arg; NM_000162.5). In Family 105, an extremely rare pathogenic frameshift variant (HNF1A: c.1136_1137del; p.Pro379ArgfsTer39; NM_000545.8) was identified. The segregation analyses of these variants also revealed that the variants largely co‐segregated with the diabetes phenotype in their respective families. Conclusion: This study clearly demonstrates the effectiveness of WES for the accurate identification of MODY subtypes in Iranian families. Moreover, these findings emphasize the need for further genetic screening programs in Iran to enhance MODY diagnosis, personalized treatment, and family genetic counseling.